---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-22-000014"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:23:17.322235+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q1 revenue up 22% to $461.9M; diluted EPS $5.03 vs $0.61 YoY

## Summary
- Q1 revenue $461.9M (+22% YoY) driven by Tyvaso ($172M, +40%) and Unituxin ($55.6M, +27%) on label expansion and Japan launch.
- Net income $239.9M (diluted EPS $5.03) vs $28.3M ($0.61) in Q1 2021; earnings surge primarily due to strong revenue and lower R&D spend.
- Tyvaso DPI NDA under FDA review with decision expected in May 2022; company awaits outcome of citizen petition and inspection issues.
- Phase 3 TETON 1 & 2 studies for IPF, PERFECT for PH-COPD, and ADVANCE trials for ralinepag are enrolling or commencing.
- Orenitram revenue grew 14% YoY to $82.8M on volume and price; Remodulin flat at $131.7M with U.S. decline offset by international orders.

## SEC filing metadata
- accession: 0001082554-22-000014
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000014/0001082554-22-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000014/uthr-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-22-000014
- JSON: https://secwatch.observer/filing/0001082554-22-000014.json
- Plain text: https://secwatch.observer/filing/0001082554-22-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.